AnichiniA.: An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTL, but does not overcome tumor escape from immune surveillance in metastatic lesions.J Exp Med, 190: 651–668, 1999.
2.
CastelliC.: Human HSP70 peptide complexes specifically activate anti-melanoma T cells.Cancer Res, 61: 222–227, 2001.
3.
MarchandM.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.Int J Cancer, 80: 219–230, 1999.
4.
ParmianiG.: Clinical and immunological results of vaccination with autologous heat-shock protein peptide complex-96 (HSPPC-96) in metastatic melanoma.Proc Am Soc Clin Oncol, 20: 252a, 2001.
5.
RenkvistN.: A list of human tumor antigens recognized by T cells.Cancer Immunol Immunother, 50: 3–15, 2001.
6.
RosenbergS.A.: Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.J Immunol, 163: 1690–1695, 1999.
7.
SrivastavaP.K.: Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world.Immunity, 8: 657–665, 1998.
